{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:55:43Z","timestamp":1787964943029,"version":"build-2784847793"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"CSF"},{"name":"Sandoz GmbH, Kundl, Austria"},{"name":"Spirit Medical Communications Ltd."},{"name":"Sandoz GmbH, Kundl, Austria"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejca.2017.10.034","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T23:40:07Z","timestamp":1512776407000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Comparing granulocyte colony\u2013stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients"],"prefix":"10.1016","volume":"89","author":[{"given":"Edoardo","family":"Botteri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andriy","family":"Krendyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2017.10.034_bib1","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib2","doi-asserted-by":"crossref","first-page":"188","DOI":"10.6004\/jnccn.2007.0019","article-title":"Myeloid growth factors. Clinical practice guidelines in oncology","volume":"5","author":"Crawford","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2017.10.034_bib3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur J Cancer"},{"issue":"suppl 5","key":"10.1016\/j.ejca.2017.10.034_bib4","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","article-title":"Hematopoietic growth factors: ESMO clinical practice guidelines for the applications","volume":"21","author":"Crawford","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3747\/co.2008.198","article-title":"Canadian supportive care recommendations for the management of neutropenia in patients with cancer","volume":"15","author":"Kouroukis","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib6","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1056\/NEJM198806023182202","article-title":"The effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium","volume":"318","author":"Gabrilove","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.034_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(88)91475-4","article-title":"Effects of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy","volume":"1","author":"Morstyn","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2017.10.034_bib8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199107183250305","article-title":"Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer","volume":"325","author":"Crawford","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2017.10.034_bib9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0959-8049(93)90376-Q","article-title":"Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy","volume":"29A","author":"Trillet-Lenoir","year":"1993","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2017.10.034_bib10","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","article-title":"A randomized, double-blind, placebocontrolled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia","volume":"90","author":"Heil","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2017.10.034_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.18553\/jmcp.2007.13.4.337","article-title":"Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3\u20134 week chemotherapy regimens in community oncology practices","volume":"13","author":"Morrison","year":"2007","journal-title":"J Manag Care Pharm"},{"issue":"5","key":"10.1016\/j.ejca.2017.10.034_bib12","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1073\/pnas.82.5.1526","article-title":"Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor","volume":"82","author":"Welte","year":"1985","journal-title":"Proc Natl Acad Sci U. S. A"},{"issue":"6","key":"10.1016\/j.ejca.2017.10.034_bib13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1182\/blood.V88.6.1907.bloodjournal8861907","article-title":"Filgrastim (r-metHuG-CSF): the first 10 years","volume":"88","author":"Welte","year":"1996","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejca.2017.10.034_bib14","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","article-title":"Blinded, randomized, multicenter study to evaluate single administration PEG-filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer","volume":"20","author":"Holmes","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib15","series-title":"Poster presented at NCCN 20th annual conference","article-title":"Comparison of EP2006, a filgrastim biosimilar, to the originator: a phase III, randomized, DoubleBlind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy","author":"Blackwell","year":"2015"},{"issue":"9","key":"10.1016\/j.ejca.2017.10.034_bib16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/annonc\/mdv281","article-title":"Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy","volume":"26","author":"Blackwell","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib17","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-13-386","article-title":"Efficacy and safety of liPEG-filgrastim versus PEG-filgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy","volume":"13","author":"Bondarenko","year":"2013","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2017.10.034_bib18","first-page":"504","article-title":"A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer","volume":"33","author":"Waller","year":"2010","journal-title":"Onkologie"},{"issue":"10","key":"10.1016\/j.ejca.2017.10.034_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1159\/000232580","article-title":"Incidence of febrile neutropenia and myelotoxicity of chemotherapy: a meta-analysis of biosimilar G-CSF studies in breast cancer, lung cancer, and non-Hodgkin's lymphoma","volume":"32","author":"Engert","year":"2009","journal-title":"Onkologie"},{"issue":"2","key":"10.1016\/j.ejca.2017.10.034_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","article-title":"Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review","volume":"23","author":"Pfeil","year":"2015","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2017.10.034_bib21","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/annonc\/mdv174","article-title":"The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppressive chemotherapy","volume":"26","author":"Lyman","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.10.034_bib22","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1007\/s00520-013-1911-7","article-title":"Clinical experience with Zarzio\u00ae in Europe: what have we learned?","volume":"21","author":"Gasc\u00f3n","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2017.10.034_bib23","volume":"vol. 5","year":"2008"},{"key":"10.1016\/j.ejca.2017.10.034_bib24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin trials"},{"key":"10.1016\/j.ejca.2017.10.034_bib25","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"issue":"7","key":"10.1016\/j.ejca.2017.10.034_bib26","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/theoncologist.2016-0011","volume":"21","author":"Blackwell","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2017.10.034_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-8-332","article-title":"XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel\/doxorubicin chemotherapy","volume":"8","author":"del Giglio","year":"2008","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2017.10.034_bib28","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.2217\/fon-2016-0016","article-title":"Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer","volume":"12","author":"Harbeck","year":"2016","journal-title":"Future Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2017.10.034_bib29","doi-asserted-by":"crossref","first-page":"586","DOI":"10.6061\/clinics\/2016(10)06","article-title":"A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients","volume":"71","author":"Hegg","year":"2016","journal-title":"Clin (Sao Paulo)"},{"issue":"2","key":"10.1016\/j.ejca.2017.10.034_bib30","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00520-016-3429-2","article-title":"A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer","volume":"25","author":"Park","year":"2017","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2017.10.034_bib31","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1007\/s10637-013-9973-4","article-title":"A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer","volume":"31","author":"Park","year":"2013","journal-title":"Invest New Drugs"},{"issue":"suppl 6","key":"10.1016\/j.ejca.2017.10.034_bib32","first-page":"1433O","article-title":"Phase 3 efficacy and safety trial of proposed pegfilgrastim biosimilar MYL-1401H vs EU-neulasta\u00ae in the prophylaxis of chemotherapy-induced neutropenia","volume":"27","author":"Waller","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx303","article-title":"Pooled analysis of two randomized, double-blind trials comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer","author":"Blackwell","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib34","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2017-0041","article-title":"Proposed biosimilar pegfilgrastim (LA-EP2006) compared with reference pegfilgrastim in Asian patients with breast cancer: an exploratory comparison from two Phase III trials","author":"Harbeck","year":"2017","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2017.10.034_bib35","series-title":"Delivering on the potential of biosimilar medicines","author":"IMS Institute for Health Informatics","year":"2016"},{"issue":"4","key":"10.1016\/j.ejca.2017.10.034_bib36","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.clinthera.2015.01.011","article-title":"Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.ejca.2017.10.034_bib37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/1078155211407367","article-title":"Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia","volume":"18","author":"Aapro","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2017.10.034_bib38","doi-asserted-by":"crossref","first-page":"e000142","DOI":"10.1136\/esmoopen-2016-000142","article-title":"Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers","volume":"1","author":"Tabernero","year":"2016","journal-title":"ESMO Open"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313977?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804917313977?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T03:40:59Z","timestamp":1660102859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804917313977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":38,"alternative-id":["S0959804917313977"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.034","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing granulocyte colony\u2013stimulating factor filgrastim and pegfilgrastim to its biosimilars in terms of efficacy and safety: A meta-analysis of randomised clinical trials in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2017.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}